| Patient | Evel Knievel |
|---|---|
| Date of birth | 1968-10-17 |
| Identifiers | MRN HR-RB001-SYN; SSN (made up) 000-01-4927 |
| Document date | 2026-01-26 |
| Author | Dale Rasmussen, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Hepatitis C results and hepatology consultation. [S]
Mr. Knievel returns two weeks after his first visit. The hepatitis C antibody was positive and the reflex test found HCV RNA, 2.35 million IU/mL, genotype 1a. Hepatitis B surface antigen, core antibody and surface antibody were all negative, so he has never had hepatitis B and is not immune; hepatitis A IgG was negative; HIV was negative. The ultrasound a week ago showed a nodular liver, a 14.2 cm spleen, no liver mass and no ascites. Dr. Okonkwo of hepatology saw him this morning, and transient elastography in her clinic measured liver stiffness at 26.8 kPa. He stopped ibuprofen and omeprazole after the first visit and uses acetaminophen twice a day and diclofenac gel on his knees; pain is a little worse in the mornings. He has cut down to about two drinks most evenings. He has had no abdominal swelling, black stools, vomiting of blood, confusion or yellow eyes. He has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Hepatitis C | Antibody positive; HCV RNA 2.35 million IU/mL; genotype 1a; never treated |
| Other serology | Hepatitis B: not infected, not immune. Hepatitis A: not immune. HIV negative |
| Staging | FIB-4 4.94; liver stiffness 26.8 kPa; nodular liver and 14.2 cm spleen on ultrasound; platelets 118 |
| Liver function | Bilirubin 1.1 mg/dL, albumin 3.6 g/dL, INR 1.1, no ascites or encephalopathy: Child-Pugh A5; MELD-Na 8 |
| Alcohol | Cut down to about two drinks most evenings |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired for months; no fever or weight loss |
| Gastrointestinal | Negative | No abdominal swelling, black stools or vomiting of blood |
| Integumentary | Positive | Small red spots on the chest; no yellowing or itching |
| Neurological | Negative | No confusion, sleep reversal or tremor |
| Musculoskeletal | Positive | Hip, knee and back pain, 6 of 10, worse in the mornings since stopping ibuprofen |
| Psychiatric | Positive | Worried about the diagnosis; PHQ-9 6; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals | One tablet twice daily with breakfast and supper | Oral route | 2021-03-01 | active | S |
| Ibuprofen 800 mg oral tablet, one tablet three times a day for joint and back pain | One tablet three times a day | Oral route | 2024-06-01 to 2026-01-12 | completed | S |
| Omeprazole 20 mg delayed-release oral capsule, one capsule daily for indigestion from ibuprofen | One capsule daily before breakfast | Oral route | 2024-06-01 to 2026-01-12 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth up to twice a day as needed for pain, no more than 2 g a day | Two tablets up to twice a day as needed; no more than 2 g a day | Oral route | 2026-01-12 | active | S |
| Diclofenac sodium 1% topical gel, 4 g to the knees up to four times a day | 4 g to each knee up to four times a day | Topical route | 2026-01-12 | active | S |
| Carvedilol 6.25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-26 to 2026-02-23 | completed | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-26 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-01-26 | Body height | 178 | cm | S |
| 2026-01-26 | Body weight | 85.6 | kg | S |
| 2026-01-26 | Body mass index (BMI) [Ratio] | 27 | kg/m2 | S |
| 2026-01-26 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-01-26 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-01-26 | Heart rate | 78 | /min | S |
| 2026-01-26 | Respiratory rate | 14 | /min | S |
| 2026-01-26 | Body temperature | 36.7 | Cel | S |
| 2026-01-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-01-26 | Liver stiffness by US.transient elastography | 26.8 | kPa | Below 7 kPa normal; above 12.5 kPa cirrhosis; 25 kPa or more clinically significant portal hypertension | High | S |
| 2026-01-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-01-26 | Total score [AUDIT-C] | 4 | {score} | S | ||
| 2026-01-26 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 6 | {score} | S |
Vital signs recorded on 2026-01-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 85.6 kg; blood pressure 136/82, pulse 78 |
| Eyes | No scleral icterus |
| Skin | Six spider angiomas on the chest and shoulders; palmar erythema; no jaundice or bruising |
| Abdomen | Liver edge firm, 2 cm below the costal margin; spleen tip palpable; no shifting dullness |
| Extremities | No leg swelling |
| Feet | Monofilament sensation intact; pulses present; no ulcers |
| Neurological | No asterixis; oriented |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Raised transaminases (ALT 88, AST 96 U/L) and low platelets (118) on today's tests, with spider angiomas and palmar erythema, in a man of 57 who received many blood transfusions after crashes before 1992 and drinks most evenings: chronic liver disease, most likely hepatitis C, must be excluded. Hepatitis C antibody with reflex RNA, hepatitis A and B serology, HIV, liver ultrasound and hepatology review ordered | resolved | confirmed | R74.01 | S — Synthetic presenting problem; no symptom or result of his real illness was made public. Superseded at the hepatology consultation. |
| Chronic hepatitis C, genotype 1a, treatment-naive, HCV RNA 2.35 million IU/mL, likely acquired through blood transfusions after crashes; synthetic modern detail linked to his publicly reported transfusion-acquired hepatitis C | active | confirmed | B18.2 | S — Synthetic genotype, viral load and timing; his hepatitis C and its likely transfusion source are documented (D). |
| Compensated cirrhosis from hepatitis C, with alcohol as a cofactor: liver stiffness 26.8 kPa, FIB-4 4.94, nodular liver and a 14.2 cm spleen on ultrasound, platelets 118; Child-Pugh A5, MELD-Na 8; no ascites, encephalopathy, jaundice or bleeding | active | confirmed | K74.69 | S — Synthetic stage of liver disease linked to his documented hepatitis C and later liver transplant. |
| Clinically significant portal hypertension in compensated cirrhosis (liver stiffness 25 kPa or more), treated with carvedilol without screening endoscopy (Baveno VII) | active | confirmed | K76.6 | S — Synthetic finding at the hepatology consultation. |
| Type 2 diabetes on metformin, A1c 7.4% | active | confirmed | E11.65 | S — Synthetic; diabetes is documented only in his last years (D), and placing it at 57 is a synthetic choice. |
| Chronic pain in the back, hips, pelvis and knees after dozens of fractures from stunt crashes, including a broken pelvis; ibuprofen stopped, and managed without oral NSAIDs or opioids | active | confirmed | G89.29 | S — Synthetic pain at the index age, anchored to his documented fractures and the pain of his later years. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Hepatitis C antibody with reflex HCV RNA and genotype | At diagnosis | Up to date | Antibody positive; HCV RNA 2.35 million IU/mL; genotype 1a (first-visit sample) |
| Laboratory | Hepatitis B surface antigen, core antibody and surface antibody | Before any HCV treatment | Up to date | All negative: no reactivation risk; vaccinate |
| Laboratory | HIV and hepatitis A IgG | Before HCV treatment | Up to date | HIV negative; hepatitis A not immune |
| Laboratory | FIB-4 | At diagnosis | Up to date | 4.94 from the first-visit results (age 57, AST 96, ALT 88, platelets 118): cirrhosis likely |
| Imaging | Transient elastography | At diagnosis | Completed today | 26.8 kPa: cirrhosis with clinically significant portal hypertension |
| Imaging | Liver ultrasound | Within six months before treatment; every six months in cirrhosis | Up to date | A week ago: nodular liver, splenomegaly, no mass, no ascites |
| Examination | Child-Pugh class and MELD-Na | At diagnosis and every six months in cirrhosis | Completed today | Child-Pugh A5; MELD-Na 8 |
| Examination | Signs of decompensation (ascites, encephalopathy, jaundice, bleeding) | Each visit in cirrhosis | Completed today | None |
| Medication safety | Drug interaction review before HCV treatment | Before treatment | Completed today | Omeprazole and ibuprofen stopped; atorvastatin allowed with monitoring; no amiodarone; no herbal supplements |
| Medication safety | Non-selective beta-blocker for clinically significant portal hypertension | Start, then titrate to blood pressure and heart rate | Completed today | Carvedilol 6.25 mg daily started |
| Examination | Screening endoscopy for varices | Only if a beta-blocker cannot be taken | Not indicated | He takes carvedilol, so Baveno VII does not call for screening endoscopy |
| Medication safety | Hepatitis A and B vaccination | At diagnosis of chronic liver disease if not immune | Completed today | Hepatitis A dose 1 and hepatitis B (CpG-adjuvanted) dose 1 today |
| Laboratory | A1c and glucose monitoring in cirrhosis | Every three months when not at goal | Up to date | A1c 7.4% in January; continuous glucose monitor ordered because the A1c can read falsely low |
| Examination | Diabetic foot examination | Yearly | Completed today | Monofilament sensation and pulses normal |
| Referral | Diabetic eye examination | Yearly | Referred | Referred; last examination over three years ago |
| Medication safety | Statin for diabetes | Age 40 to 75 with diabetes | Completed today | Atorvastatin 20 mg started; safe in compensated cirrhosis |
| Survey | Alcohol use (AUDIT-C) | Each visit in liver disease | Completed today | AUDIT-C 4: cutting down; goal is no alcohol |
| Survey | Pain score and function | Each visit | Completed today | 6 of 10 after stopping ibuprofen; acetaminophen up to 2 g a day and topical diclofenac |
| Referral | Hepatology | At diagnosis of hepatitis C with cirrhosis | Completed today | Seen this morning; recommendations in the consultation note |
| Survey | Depression screen (PHQ-9) | At diagnosis and when treatment changes | Completed today | PHQ-9 6; no thoughts of self-harm |
Goal progress:
Immunizations given today: Hepatitis A vaccine, adult, dose 1 of 2; Hepatitis B vaccine (recombinant, CpG adjuvanted), dose 1 of 2 [S]
Guideline basis: AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023); AASLD-IDSA HCV Guidance: Monitoring patients who are starting HCV treatment, are on treatment, or have completed therapy (2026); EPCLUSA (sofosbuvir and velpatasvir) tablets, prescribing information (2025); Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78(6):1922-1965 (PMID 37199193) (2023); de Franchis R, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022;76(4):959-974 (PMID 35120736) (2022); Kaplan DE, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 2024;79(5):1180-1211 (PMID 37870298) (2024); Biggins SW, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the AASLD. Hepatology 2021;74(2):1014-1048 (PMID 33942342) (2021); Crabb DW, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the AASLD. Hepatology 2020;71(1):306-333 (PMID 31314133) (2019); Rakoski M, Goyal P, Spencer-Safier M, et al. Pain management in patients with cirrhosis. Clin Liver Dis (Hoboken) 2018;11(6):135-140 (PMID 30992804) (2018); Dowell D, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022;71(3):1-95 (PMID 36327391) (2022); American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S61-S88 (PMID 41358897) (2026); American Diabetes Association. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S132-S149 (PMID 41358894) (2026); Hepatitis C Virus Infection in Adolescents and Adults: Screening (2020); Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, osteoporosis and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Physical therapy assessment next week. Antiviral treatment to start at the next visit in four weeks, with the second hepatitis B dose and carvedilol titration. Call for abdominal swelling, black stools, vomiting of blood, confusion or yellow eyes. Next scheduled visit 2026-02-23: day 1 of sofosbuvir-velpatasvir: drug interaction check, carvedilol titration, glucose monitoring, vitamin D, and the bone density plan. [S]